The United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has authorized use of the Janssen single-dose COVID-19 vaccine. The UK has placed an order for 20 million doses, which are scheduled to be accessible in the country later this year, according to the regulatory body.
Single-dose Janssen COVID-19 vaccine fourth to be approved in the UK
Johnson & Johnson’s Janssen single-dose COVID-19 vaccine is the fourth vaccine after the Oxford-AstraZeneca, Pfizer-BioNTech and Moderna alternatives, to be approved by the MHRA. Approximately, 74.2% of adults have been vaccinated once and 47.3% of adults have had two vaccines in the UK, according to the latest figures confirmed by the UK’s Health Minister Matt Hancock.
The U.K. Health Minister Matt Hancock tweeted:
Janssen COVID-19 vaccine shows 85% success in preventing hospitalization with single-dose
According to Phase 3 trial data, the vaccine was shown to be 67% effective in preventing COVID-19 infections and 85% successful in avoiding severe COVID cases and hospitalizations. It has yet to be tested against a variation initially discovered in India that is transmitting fast but at low levels in the UK.
The vaccine, created by Johnson & Johnson’s pharmaceutical division Janssen, is based on the same adenovirus technology as the Oxford-AstraZeneca vaccine it is deemed more suitable for older individuals rather than youngsters. Both vaccines use modified COVID-19 versions to deliver instructions to the immune system to generate an adequate immune response producing antibodies.
Since Health Officials have expressed worry about possible links between the vaccination and the formation of uncommon blood clots in the brain, in individuals under 40 years old, in the UK they have been given alternatives to AstraZeneca, but still, regulators have determined that the vaccination’s benefits exceed the risks.
Initially, the Vaccine Taskforce of the British government had secured 30 million doses, but the order was revised as the immunization program continues at a “unprecedented scale and pace,” according to the UK government.
The UK’s Joint Committee on Vaccination and Immunisation (JCVI) will issue guidance on exactly which demographics should be prioritizsd in the Belgian-produced vaccine rollout. But because the Janssen COVID-19 vaccine can be readily stored and transported at fridge temperatures of 2 to 8 degrees Celsius (35.6 to 46.4 degrees Fahrenheit) making its storage and transportation easier than some alternative vaccines and it is authorized for individuals aged 18 and over, it is likely to be used as a booster jab for care home patients ahead of winter. Administered in such a single shot, it may be easier to reach vulnerable patients in nursing homes and those who live in distant areas.
UK government-funded clinical trial evaluates COVID-19 ‘booster’ vaccines
The COVID-19 vaccine, developed by Janssen, is presently being tested in a new government-funded clinical trial which started on 19th May, to confirm the safety and efficacy of giving people a third dose to boost their viral immunity. Patients must get two doses of the Oxford-AstraZeneca, Pfizer-BioNTech, and Moderna vaccines to achieve optimal immunity. Before the Janssen vaccine is rolled out, the Joint Committee on Vaccination and Immunisation in the United Kingdom will issue updated recommendations for its usage.
The United Kingdom government has also stated that it was in touch with vaccine manufacturers to assist in increasing supplies and prepare for a possible immunization booster program later in 2021.
No listings were found matching your selection.